RGEN News and Press, Repligen Corporation From 11/15/19

Agilent (NYSE: A ) initiated with Hold rating and $85 (11% upside) price target at Stifel. More news on: Agilent Technologies, Inc., Avantor, Inc., Bio-Techne Corporation, Healthcare stocks news, Stocks on the move, , Read more ...

Investment Thesis I like the look of Repligen (RGEN). The company operates in a growing market, supplying tools for the manufacture of biologic drugs, most notably monoclonal antibodies. It has a proven ability to make strategic acquisitions that complement its business model and capabilitie...

Repligen Corporation (RGEN) Q3 2019 Earnings Conference Call October 31, 2019 08:30 AM ET Company Participants Sondra Newman - Global Head of Investor Relations Tony Hunt - President and Chief Executive Officer Jon Snodgres - Chief Financial Officer Conference Call Participant...

Image source: The Motley Fool. Repligen   (NASDAQ: RGEN) Q3 2019 Earnings Call Oct 31, 2019 , 8:30 a.m. ET Operator Continue reading

After an eventful first half of the year, Repligen (NASDAQ: RGEN) turned in a relatively ho-hum performance in the third quarter. To be fair, revenue grew 40% year over year and the company raised full-year 2019 revenue guidance, but investors have come to expect that from the bioprocessing ...

Repligen (NASDAQ: RGEN ): Q3 Non-GAAP EPS of $0.26; GAAP EPS of $0.03 misses by $0.03 . More news on: Repligen Corporation, Earnings news and commentary, Healthcare stocks news, Read more ...

Reports quarterly revenue of $69.4 million, representing 40% reported growth and 28% organic growth year-over-year Raises revenue guidance to $267-$270 million for full year 2019, representing 31%-32% organic growth WALTHAM, Mass., Oct. 31, 2019 (GLOBE NEWSWIRE) -- Repligen Corpor...

WALTHAM, Mass., Oct. 23, 2019 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN) today announced that the Company will report its third quarter 2019 financial results on Thursday, October 31, 2019. The Company will issue a press release before the market opens and will host a conference...

It may not be as sexy as biopharmaceutical companies developing gene therapies or tailoring the next big cellular medicines, but Repligen (NASDAQ: RGEN) has certainly rewarded investors through its leadership position in bioprocess engineering. The stock has delivered a 10-year return of 1,4...

Shares of Repligen (NASDAQ: RGEN) fell more than 17% last month, according to data provided by S&P Global Market Intelligence . In fact, September was the stock's worst month of 2019, although there wasn't any company-specific news to justify the drop. This simply appears to be a case o...